Hispanic/Latino and Non-Hispanic BlAck Patients Treated with NiRaparib and Abiraterone Acetate Plus Prednisone for Metastatic HOrmone Sensitive Prostate Cancer with Deleterious Homologous RecombinatioN Repair Alterations: a Phase II, Open Label StudY
Latest Information Update: 16 Jun 2025
At a glance
- Drugs Abiraterone acetate (Primary) ; Abiraterone acetate/niraparib (Primary) ; Docetaxel (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms HARMONY
Most Recent Events
- 10 Jun 2025 Planned initiation date changed from 1 May 2025 to 1 Jul 2025.
- 04 May 2025 Planned initiation date (estimated date of first patient enrollment) changed from 1 Apr 2025 to 1 May 2025.
- 22 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.